Gene therapy for chronic myelogenous leukemia (CML): A retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo

Blood

Volumn 90, Issue 12, 1997, Pages 4687-4698

  Zhao, Robert C H ^b   McIvor, R Scott ^b   Griffin, James D ^b   Verfaillie, Catherine M ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; VIRUS VECTOR;

ARTICLE; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; GENE REARRANGEMENT; GENE THERAPY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0031453998     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.12.4687.4687_4687_4698     Document Type: Article

References (42)

1. Fialkow PJ, Jacobson RJ, Papayannopoulou TH: Chronic myelocytic leukemia: Clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med 63:125, 1977
2. Bartram CR, deKlein A, Hagemeijer A, van Agthoven T, Geurts van Kessel A, Bootsma D, Grosveld G, Ferguson-Smith MA, Davies T, Stone M: Translocation of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukemia. Nature 306:277, 1983
3. Rowley JD: The Philadelphia chromosome translocation: A paradigm for understanding leukemia. Cancer 65:2178, 1990
4. BCRIABL gene of the Philadelphia chromosome. Science 247:824, 1990
5. Gishizky ML, Witte ON: Initiation of dysregulated growth of multipotent progenitor cells by bcr-abl in vitro. Science 256:836, 1992
6. Snyder DS, McGlave PB: Treatment of chronic myelogenous leukemia with bone marrow transplantation. Hematol Oncol Clin North Am 4:535, 1990
7. McGlave PB, Bartsch G, Anasetti C, Ash R, Beatty P, Gajewski J, Kernan NA: Unrelated donor bone marrow transplantation therapy for chronic myelogenous leukemia: Initial experience of the National Marrow Donor Program. Blood 81:543, 1993
8. McGlave PB, DeFabrtiis P, Deisseroth A, Goldman J, Barnett M, Reiffers J, Simonsson B, Carella A, Aeppli D: Autologous transplant therapy for chronic myelogenous leukemia prolongs survival: Results from eight transplant centers. Lancet 343:1486, 1994
9. Deisseroth AB, Zhifei Z, Claxton D, Hanania EG, Siqing F, Ellerson, Goldberg L, Thomas M, Janiceck K, Anderson WF, Hester J, Korbling M, Durett A, Moen R, Berenson R, Heimfeld S, Hamer J, Calvert L, Tibbits P, Talpaz M, Kantarjian H, Champlin R, Reding C: Genetic marking shows that Ph+ cells present in autlogous marrow of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow transplants in CML. Blood 83:3068, 1994
10. Mackinnon S, Barnett L, Heller G, O'Reilly RJ: Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia. Blood 83:3409, 1994
11. Corey CA, DeSilva AD, Holland CA, Williams DA: Serial transplantation of MTX-resistant bone marrow: Protection of murine recipients from drug toxicity by progeny of transduced stem cells. Blood 75:337, 1990
12. Vinh DB-N, McIvor RS: Selective expression of drug-resistant dihydrofolate reductase activity in mice transduced with DHFR-retroviruses and administered methotrexate. J Pharm Exp Therapeutics 267:989, 1993
13. Zhao SC, Li MX, Banerjee D, Schweitzer BI, Mineishi S, Gilboa E, Bertino JR: Long-term protection of recipient mice from lethal doses of methotrexate by marrow infected with a double-copy vector retrovirus containing a mutant dihydrofolate reductase. Cancer Gene Therapy 1:27, 1994
14. May C, Gunther R, McIvor RS: Protection of mice from lethal doses of methotrexate by transplantation with transgenic marrow expressing drug-resistant dihydrofolate reductase activity. Blood 86:2439, 1995
15. Szczylik C, Sikorski T, Nicolaitidis NC, et al: Selective inhibition of leukemia cell proliferation by BCR-ABL anti-sense oligonucleotides. Science 253:562, 1991
16. Morris JA, McIvor RS: Saturation mutagenesis at dihydrofolate reductase codons 22 and 31. A variety of amino acid substitutions conferring methotrexate resistance. Biochem Pharmacol 47:1207, 1994
17. Braun SE, McIvor RS, Davidson AS, Hanna M, Traycoff CM, Berebetsky DA, Gonin R, Broxmeyer HE, Cornetta K: Retrovirally mediated gene transfer of Arg22 and Tyr22 forms of dihydrofolate reductase into the hematopoietic cell line K562: A comparison of methotrexate resistance. Cancer Gene Ther 4:26, 1997
18. Markowitz D, Goff S, Bank A: A safe packaging line for gene transfer: Separating viral genes on two different plasmids. J Virol 62:1120, 1988
19. Bauer TR Jr, Miller AD, Hickstein DD: Improved transfer of the leukocyte integrin CD18 subunit into hematopoietic cell lines by using retroviral vectors having a gibbon ape leukemia virus envelope. Blood 86:2379, 1995
20. Miller AD, Buttimor C: Redesign of retrovirus packaging lines to avoid recombination leading to helper virus production. Mol Cell Biol 6:2895, 1986
21. Carlesso N, Griffin JD, Druker BJ: Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line. Oncogene 9:149, 1994
22. Orchard PJ, Detrick RA, Gorden K, Dunbar CE, Vallera DA, Taylor P, McIvor RS, Blazar BR: Retroviral-mediated transfer of the murine interleukin-3 gene engineered for intracellular retention results in a myeloproliferative syndrome but is associated with circulating interleukin-3 levels. Exp Hematol 21:1245, 1993
23. Sirard C, Laneuville P, Dick JE: Expression of bcr-abl abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism. Blood 83:1575, 1994
24. Verfaillie CM, Bhatia R, Miller W, Mortari F, Roy V, Burger S, McCullough J, Stieglbauer K, Dewald G, Heimfeld S, Miller JS, McGlave PB: BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients. Blood 87:4770, 1996
25. Ausubel FM, Brent R, Kingston RE: Current Protocols in Molecular Biology. New York, NY, Wiley & Sons, 1987
26. Cortez D, Kadlec L, Pendergast AM: Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol Cell Biol 15:5531, 1995
27. Goga A, McLaughlin J, Afar DE, Saffran DC, Witte ON: Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell 82:981, 1995
28. Nieborowska-Skorska M, Ratajczak MZ, Calabretta B, Skorski T: The role of c-Myc protooncogene in chronic myelogenous leukemia. Folia Histochem Cytobiol 32:231, 1994
29. Philpott NJ, Turner AJ, Scopes J, Westby M, Marsh JC, Gordon-Smith EC, Dalgleish AG, Gibson FM: The use of 7-amino actinomycin D in identifying apoptosis: Simplicity of use and broad spectrum of application compared with other techniques. Blood 87:2244, 1996
30. Bi S, Lanza F, Goldman JM: The involvement of "tumor suppressor" p53 in normal and chronic myelogenous leukemia hemopoiesis. Cancer Res 54:582, 1994
31. Sanchez-Garcia I, Grutz G: Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc Natl Acad Sci USA 92:5287, 1995
32. Gordon MY, Dowdling CR, Riley GP, Goldman JM, Greaves MF: Altered adhesive interactions with marrow stroma of hematopoietic progenitor cells in chronic myeloid leukaemia. Nature 328:342, 1984
33. Verfaillie CM, Hurley R, Lundell BI, Bhatia R: Integrin-mediated regulation of hematopoiesis: Do BCR-ABL induced defects in integrin function underlie the abnormal circulation and proliferation of CML progenitors? Acta Haematol 97:40, 1997
34. Verfaillie CM, McCarthy JB, McGlave PB: Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. J Clin Invest 90:1232, 1992
35. Bhatia R, Wayner EA, McGlave PB, Verfaillie CM: Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function. J Clin Invest 94:384, 1994
36. Ghaffari S, Dougherty GJ, Lansdorp PM, Eaves AC, Eaves CJ: Differentiation-associated changes in CD44 isoform expression during normal hematopoiesis and their alteration in chronic myeloid leukemia. Blood 86:2976, 1995
37. Renshaw MW, McWhirter JR, Wang JY: The human leukemia oncogene bcr-abl abrogates the anchorage requirement but not the growth factor requirement for proliferation. Mol Cell Biol 15:1286, 1995
38. Eaves AC, Cashman JD, Gaboury LA, Kalousek DK, Eaves CJ: Unregulated proliferation of primitive chronic myeloid leukemia progenitors in the presence of normal marrow adherent cells. Proc Natl Acad Sci USA 83:5306, 1986
39. Allen PB, Morgan GJ, Wiedemann LM: Philadelphia chromosome-positive leukaemia: The translocated genes and their gene products. Baill Clin Haematol 5:897, 1992
40. Chen Z, Tong JH, Dong S, Zhu J, Wang ZY, Chen SJ: Retinoic acid regulatory pathways, chromosomal translocations, and acute promyelocytic leukemia. Genes Chromosom Cancer 15:147, 1996
41. Freier SM, Kierzek R, Jaeger JA, Sugimoto N, Caruthers MH, Neilson T, Turner DH: Improved free-energy parameters for predictions of RNA duplex stability. Proc Natl Acad Sci USA 83:9373, 1986
42. Zuker M, Stiegler P: Optimal computer folding of large RNA sequences using thermodynamics and auxiliary information. Nucleic Acids Res 9:133, 1981